Evidence map›Paper›PMID 30803362›Full record

ArticleTechnology in cancer research & treatment2019

Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy.

Satoshi Funayama, Hiroshi Onishi, Kengo Kuriyama, Takafumi Komiyama, Kan Marino, Masayuki Araya, Ryo Saito, Shinichi Aoki, Yoshiyasu Maehata, Hotaka Nonaka and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Carbon-ion radiotherapy for urological cancers.International journal of urology : official journal of the Japanese Urological Association · 2022
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Satoshi Funayama1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Hiroshi Onishi1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan.ORCID 0000-0002-3512-1166
Kengo Kuriyama2 Department of Radiology, Shizuoka General Hospital, Shizuoka, Japan.
Takafumi Komiyama1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Kan Marino1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Masayuki Araya3 Department of Radiology, Center of Proton Therapy, Aizawa Hospital, Nagano, Japan.
Ryo Saito1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Shinichi Aoki1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Yoshiyasu Maehata1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Hotaka Nonaka4 Department of Radiology, Fujiyoshida Municipal Medical Center, Yamanashi, Japan.
Licht Tominaga5 Department of Radiology, Toranomon Hospital, Tokyo, Japan.
Juria Muramatsu1 Department of Radiology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Hiroshi Nakagomi6 Department of Urology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Manabu Kamiyama6 Department of Urology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Masayuki Takeda6 Department of Urology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
University of Yamanashi · JPAizawa Hospital · JPShizuoka General Hospital · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the safety and efficacy of stereotactic body radiation therapy for primary lesion of renal cell carcinoma with long-term and regular follow-up of tumor size and renal function.

methodsThis prospective study included 13 patients treated with stereotactic body radiation therapy for primary lesion of stage I renal cell carcinoma between August 2007 and June 2016 in our institution. Diagnosis of renal cell carcinoma was made by 2 radiologists using computed tomography or magnetic resonance imaging. A dosage of 60 Gy in 10 fractions or 70 Gy in 10 fractions was prescribed. The higher dose was selected if dose constraints were satisfied. Tumor response on imaging examination, local progression-free rate, overall survival, and toxicity were assessed.

resultsThe mean follow-up period was 48.3 months (range: 11-108 months). The tumors showed very slow but continuous response during long-term follow-up. Three cases (23.1%) showed transient progression during the short follow-up. The mean duration until the day on which partial response was confirmed among the partial or complete response cases was 22.6 months (95% confidence interval, 15.3-30.0 months). Local progression-free rate was 92.3% for 3 years and overall survival rate 91.7% for 2 years and 71.3% for 3 years. Twelve cases (92.3%) had impaired renal function at baseline. Renal function decreased slowly and mildly in most of the cases, but 2 cases of solitary kidney showed grade 4 or 5 renal dysfunction.

conclusionAll renal tumors decreased in size slowly but continuously for years after stereotactic body radiation therapy. Renal cancer can be treated radically with stereotactic body radiation therapy as a radiosensitive tumor, but careful attention should be given in cases with solitary kidney.

Indexed as

AgedAged, 80 and overFemaleFollow-Up StudiesHumansKidney NeoplasmsMaleMiddle AgedPrognosisProspective StudiesRadiosurgeryRadiotherapy DosageRadiotherapy Planning, Computer-AssistedSurvival RateTomography, X-Ray Computedkidney cancerprimary lesionstereotactic body radiation therapy (SBRT)toxicitytumor response

Identifiers

PMID30803362
PMCPMC6373992
OpenAlexW2907719701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.